If your doctor has mentioned a PSMA PET scan, it likely means your care team is evaluating whether Lu-177 PSMA therapy could be a next step for your metastatic castration-resistant prostate cancer (mCRPC). This article is for men on that path - typically after one or more hormone therapies and chemotherapy have stopped controlling the disease.
The scan itself is not a treatment. It is an eligibility test. Before any decision about lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) is made, your nuclear medicine team needs to know whether your cancer cells carry enough of a protein called PSMA - prostate-specific membrane antigen - for the therapy to reach and affect them. The PSMA PET scan answers that question with a level of precision that older imaging cannot match.
What is a PSMA PET scan?
PSMA is a protein found on the surface of most prostate cancer cells. In advanced prostate cancer, PSMA levels on tumor cells are often significantly elevated compared to normal tissue. A PSMA PET scan works by injecting a small amount of a radioactive tracer designed to find this protein. Wherever the tracer binds to PSMA-bearing cells, those areas appear as bright spots on the scan image.
The most widely used tracer is gallium-68 (Ga-68) PSMA-11. According to the Prostate Cancer Foundation, the FDA approved Ga-68 PSMA-11 (brand name Locametz) as a companion diagnostic specifically for prostate cancer imaging. The imaging is almost always combined with a CT scan, making it a PSMA PET/CT. The PET portion shows where in the body the tracer has collected. The CT portion shows the anatomy around those areas, so the team can pinpoint exactly where any PSMA-positive lesions are located.
According to the National Cancer Institute, PSMA PET/CT can detect prostate cancer spread with greater accuracy than older methods such as conventional bone scans and CT scans alone.
How do you prepare for the scan?
Preparation for a PSMA PET scan is simpler than many patients expect. Every center will give you written instructions specific to their protocol. Always follow those over any general guidance. The steps below reflect commonly used clinical approaches.
Hydration
Drink plenty of water from the day before the scan until you arrive at the center. Good hydration helps the tracer clear from your kidneys and bladder quickly. Drinking water helps produce clearer scan images. Most centers will also encourage you to keep drinking water during the waiting room period after injection.
Fasting
Most centers do not require fasting before a Ga-68 PSMA scan. Some protocols ask that you avoid food for up to four hours before the tracer injection. Your center will tell you what applies. If you have diabetes or take insulin, mention this when you book the appointment. The team can give you adjusted guidance for your situation.
Exercise
Avoid strenuous physical activity for 24 hours before the scan. Heavy exercise can change how the tracer distributes in the body and may reduce image quality.
Medications
Continue all prescribed medications as normal unless your care team specifically tells you otherwise. Do not pause hormone therapy or any other cancer treatment without asking your oncologist first. The scan is designed to be performed while you are on ongoing treatment.
What to bring and wear
Wear loose, comfortable clothing without metal zips or underwire. You may be asked to change into a hospital gown. Bring your appointment letter, any previous imaging reports or discs, and a current list of your medications. If you have had previous bone scans, CT scans, or PET scans, bring those images if possible. A comparison helps the nuclear medicine team read your new results in context and notice any changes.
Scan-day anxiety is very common. A poor night of sleep before an important appointment can make it harder to get through. If you have trouble sleeping or managing stress before the scan, talk to your GP about options.
What happens on scan day - step by step
Here is a brief overview you can share with a family member or caregiver who will be with you.
- Arrival and check-in: You register at the nuclear medicine department. Staff will review your instructions, confirm your medical history, and check your current medications.
- IV placement: A nurse places a small intravenous (IV) line in your arm or hand. This is the route used to inject the tracer.
- Tracer injection: The radioactive tracer is injected through the IV line. It is a clear liquid. The injection takes only a few seconds and is no more uncomfortable than a standard blood draw.
- Waiting period: You rest quietly for 50 to 100 minutes while the tracer circulates and binds to PSMA-expressing cells, as described by the Society of Nuclear Medicine and Molecular Imaging. Avoid excessive movement or talking during this time. Muscle activity can affect how the tracer distributes in the body.
- Bladder void: Just before imaging begins, you will be asked to empty your bladder. PSMA tracer concentrates in urine. A full bladder creates artifacts on the scan that can obscure nearby structures and make the images harder to read accurately.
- PET/CT imaging: You lie flat on a padded table that moves slowly through the scanner. The scanner is shaped like a large ring - open at both ends, not an enclosed tunnel. Most patients find it far less confining than an MRI. The combined PET and CT scan typically takes 20 to 40 minutes. You need to lie still. Breathing normally is fine.
- After the scan: The IV line is removed. You can eat and drink as normal straight away. Continue drinking extra fluids for the rest of the day to help flush the remaining tracer from your body through urine. You can drive home unless sedation was used for any reason, which is rare for this type of imaging.
Plan for the full appointment to take two to three hours from arrival to departure, including the waiting period after injection. Bring a book or something to listen to during the rest phase.
What is the scanner looking for?
The nuclear medicine physician who reads your scan compares how brightly each area of concern lights up against a reference level. In most clinical protocols, the liver serves as the background reference point. A lesion is considered PSMA-positive when it glows more intensely than the liver on the PET images.
This comparison uses the same standard as the VISION trial - the large clinical study that led to FDA approval of lutetium Lu-177 vipivotide tetraxetan for mCRPC. In that trial, patients were eligible for treatment only if at least one lesion showed PSMA uptake greater than the liver, and if no lesions showed clearly low or absent PSMA expression. A review of the VISION trial imaging substudy published in the Journal of Nuclear Medicine confirmed that experienced nuclear medicine physicians generally reach consistent conclusions when applying these criteria to the same scan.
Your scan report will describe the location of each visible lesion, how intensely each site takes up the tracer, and any other findings relevant to your treatment planning. Terms like "avid," "mildly avid," or "non-avid" describe uptake levels in graded language. Ask your oncologist to go through the report with you line by line. You do not need to interpret it alone.
For more help understanding the language in your scan report before that conversation, the guide on how to read your PSMA PET scan explains the key terms in patient-friendly language.
When will you get your results?
Most centers issue the formal scan report within one to seven working days. Some high-volume nuclear medicine departments that perform many PSMA scans can turn results around faster. If your situation is clinically urgent, ask the referring oncologist whether expedited reporting is available at your center.
The report goes first to your referring oncologist or urologist. In many hospitals, a multidisciplinary team - including the nuclear medicine physician, your oncologist, and sometimes a radiation oncologist - will review the results together before making a recommendation. This review adds a day or two but typically leads to a more considered next step for your specific situation.
You are entitled to a copy of your scan report, and you can request the digital imaging files (usually provided on a disc or as a secure download). Request both. If you decide to seek a second expert opinion later, having your own copy of the raw scan data and the written report will save significant time and avoid unnecessary delays.
What the results mean for your Lu-177 eligibility
A clearly positive scan - where at least one lesion shows strong PSMA uptake above the liver threshold, with no large PSMA-negative sites - is generally the first condition that has to be met before Lu-177 PSMA therapy can proceed. A positive scan result does not guarantee treatment will start, but it is a necessary first gate.
After a positive scan, your team will assess several other factors before confirming eligibility. These typically include kidney function, blood counts, overall performance status, and the history of treatments you have already received. You can read more about the full range of pre-treatment checks in the guide on what blood tests and scans you need before Lu-177 PSMA treatment.
If you want an independent nuclear medicine review of your imaging, a specialist second opinion can help. They can assess whether your imaging meets Lu-177 eligibility criteria and advise on next steps if it does not - including whether a repeat scan or an alternative approach makes clinical sense.
If the scan does not show enough PSMA expression
Not every patient who has a PSMA PET scan will qualify for Lu-177 therapy. The VISION trial imaging substudy found that a meaningful proportion of enrolled candidates did not meet the PSMA-positive imaging threshold, according to the published substudy results. This is a known feature of PSMA-based patient selection. While receiving this result is disappointing, it is useful clinical information. It steers your care team toward therapies that are more likely to work for your cancer's specific biology.
Low or absent PSMA expression is sometimes seen in patients who have received many prior lines of treatment. Some patients have mixed disease, where some lesions are PSMA-positive and others are not. If your scan shows a mixed picture, your multidisciplinary team will need to weigh this carefully before recommending a course of action.
If the result is borderline or your current team is uncertain how to interpret it, seeking a specialist second opinion on the imaging is a reasonable and often valuable step. The article on getting a second opinion on Lu-177 PSMA eligibility explains what that process looks like and what documents to prepare before the review.
A negative or borderline scan result is a finding, not a final verdict. It redirects the conversation toward other options - including other targeted therapies, chemotherapy, or clinical trials - that may still offer real and meaningful benefit.
When to talk to your doctor: Talk to your oncologist before the scan if you have concerns about your current medications, kidney function, or any history of allergic reactions to imaging agents. After the scan, ask your team to walk you through the report and explain exactly how the findings affect your next steps. If the result is unclear or you want a second perspective on your eligibility, raising that directly with your oncologist is entirely reasonable and should be encouraged.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Do I need to fast before a PSMA PET scan?
Most centers do not require fasting before a Ga-68 PSMA PET scan. Some protocols ask you to avoid food for up to four hours before the tracer injection. Your nuclear medicine team will give you specific written instructions when you book. If you have diabetes or take insulin, let the team know in advance so they can give you adjusted guidance.
How long does the entire PSMA PET scan appointment take?
Plan for two to three hours from arrival to departure. The tracer injection itself takes only a few seconds. After that, you wait 50 to 100 minutes for the tracer to circulate and bind to cancer cells. The actual PET and CT scanning then takes 20 to 40 minutes. Most patients can leave and return to normal activities straight after the scan.
How long does it take to get PSMA PET scan results?
Most centers issue the formal scan report within one to seven working days. The report goes to your referring oncologist or urologist first. Some hospitals have a multidisciplinary team review the results before making a recommendation, which may add a day or two. Ask your oncologist when to expect the report so you have a clear timeline.
What does it mean if my PSMA PET scan is negative or the uptake is very faint?
A negative or low-uptake scan suggests your cancer cells may not carry enough PSMA protein for Lu-177 PSMA therapy to be an effective option at this time. This happens in some patients, particularly those who have had many prior treatments. It does not mean there are no other options. It means your care team needs to look at different approaches. A second specialist opinion on the scan is a reasonable step if the result is borderline or your team is uncertain.
Can I drive home after a PSMA PET scan?
Yes, in most cases you can drive yourself home. The procedure does not involve sedation, and the tracer dose is small. The main recommendation after the scan is to drink extra fluids for the rest of the day to help clear the tracer from your body through urine. If sedation was given for any reason - which is rare - arrange for someone else to drive you home.
Is a PSMA PET scan the same as a bone scan or a regular CT scan?
No. A conventional bone scan uses a different tracer and detects areas of high bone activity in general - not PSMA expression specifically. A standard CT scan shows anatomy but cannot identify the PSMA protein on cancer cells. A PSMA PET/CT is more precise than either older test for detecting prostate cancer spread throughout the body. For Lu-177 PSMA eligibility assessment, your team specifically needs a PSMA PET/CT - not a bone scan or conventional CT.
